tailieunhanh - Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: A multicenter retrospective study

Although nivolumab (anti-programmed cell death-1 antibody) is a promising approach for advanced gastric cancer (AGC), the response rate remains limited. The aim of this multicenter retrospective study was to determine if clinical features could serve as prognostic factors of the efficacy of nivolumab in patients with AGC. | Sano et al. BMC Cancer 2022 22 22 https s12885-021-09118-3 RESEARCH ARTICLE Open Access Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer a multicenter retrospective study Akihiko Sano1 Makoto Sohda1 Nobuhiro Nakazawa1 Yasunari Ubukata1 Kengo Kuriyama1 Akiharu Kimura1 Norimichi Kogure1 Hisashi Hosaka2 Atsushi Naganuma3 Masanori Sekiguchi4 Kana Saito5 Kyoichi Ogata1 Makoto Sakai1 Hiroomi Ogawa1 Ken Shirabe1 and Hiroshi Saeki1 Abstract Background Although nivolumab anti-programmed cell death-1 antibody is a promising approach for advanced gastric cancer AGC the response rate remains limited. The aim of this multicenter retrospective study was to deter- mine if clinical features could serve as prognostic factors of the efficacy of nivolumab in patients with AGC. Methods Fifty-eight patients with AGC who were treated with nivolumab as a third or later line from October 2017 to December 2018 at any of five clinical sites were enrolled in the study. The correlation between the best over- all response and clinical features was investigated. Overall survival and progression-free survival after initiation of nivolumab were calculated and clinical features that could be predictors of the prognosis were sought. Results The disease control rate DCR for nivolumab was and was significantly correlated with perfor- mance status p metastasis to one organ p and grade 2 or higher immune-related adverse events p . There was also a significant association between response to nivolumab and ability to receive subsequent chemotherapy p . In the analysis of overall survival the following variables were identified as being signifi- cantly associated with a poor outcome Eastern Cooperative Oncology Group performance status 1 prior treat- ment with trastuzumab no immune-related adverse events lack of a response to nivolumab and inability to receive subsequent .

• Y khoa - Dược
• BMC Cancer
• Advanced gastric cancer
• Performance status
• Immune related adverse events
• Anti programmed cell death 1 antibody
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study